Buffalo, NY – December 4, 2015 – Empire Genomics, LLC (www.empiregenomics.com), a leading provider of oncology molecular diagnostics products and services, which enable precision medicine has announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to support their DOD Transformative Impact Award: Toward the Practice of Precision Medicine: A Biomarker Validation Coordinating Center.
With MSK serving as the coordinating site, five additional hospitals have joined together to revolutionize the clinical management of prostate cancer – to enable the practice of precision medicine in the near term – by developing analytically validated assays for predictive biomarkers for use in prospective clinical trials at all points in the disease. Under the agreement, Empire Genomics will manufacture molecular diagnostic assays exclusively to support the Award, a Multicenter Assay Validation Program for the development of clinically validated assays associated with prostate cancer. Empire Genomics will also potentially use its clinical lab to provide a testing standard for this study.
“Standardizing the testing methods and reporting metrics is one of the core goals of the DOD Transformative Impact Award,” said Jake Vinson, CEO of the Prostate Cancer Clinical Trials Consortium (PCCTC) “Empire’s manufacturing and CLIA laboratory facilities are well suited to support the multi-investigator lead studies.”
Tony Scarpello, VP of Business Development at Empire Genomics said, “We’re very excited to partner our molecular diagnostic service capabilities within this DOD project to specifically address clinical assay validation. In order to make the promise of precision medicine a reality we must insure the testing products are robust enough to meet the rigorous clinical standards and that results from lab to lab are identical.”
Empire will provide standard FISH assays to member institutions in addition to optimized protocols, standard custom production lots as well as web based project management tools.
About Empire Genomics
Empire Genomics, LLC is a global molecular diagnostics firm specializing in oncology products and clinical services. Technologies available include FISH, genotyping services, Next Generation Sequencing, as well as gene expression. The organization is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and guiding ideal therapeutic interventions.
With MSK serving as the coordinating site, five additional hospitals have joined together to revolutionize the clinical management of prostate cancer – to enable the practice of precision medicine in the near term – by developing analytically validated assays for predictive biomarkers for use in prospective clinical trials at all points in the disease. Under the agreement, Empire Genomics will manufacture molecular diagnostic assays exclusively to support the Award, a Multicenter Assay Validation Program for the development of clinically validated assays associated with prostate cancer. Empire Genomics will also potentially use its clinical lab to provide a testing standard for this study.
“Standardizing the testing methods and reporting metrics is one of the core goals of the DOD Transformative Impact Award,” said Jake Vinson, CEO of the Prostate Cancer Clinical Trials Consortium (PCCTC) “Empire’s manufacturing and CLIA laboratory facilities are well suited to support the multi-investigator lead studies.”
Tony Scarpello, VP of Business Development at Empire Genomics said, “We’re very excited to partner our molecular diagnostic service capabilities within this DOD project to specifically address clinical assay validation. In order to make the promise of precision medicine a reality we must insure the testing products are robust enough to meet the rigorous clinical standards and that results from lab to lab are identical.”
Empire will provide standard FISH assays to member institutions in addition to optimized protocols, standard custom production lots as well as web based project management tools.
About Empire Genomics
Empire Genomics, LLC is a global molecular diagnostics firm specializing in oncology products and clinical services. Technologies available include FISH, genotyping services, Next Generation Sequencing, as well as gene expression. The organization is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and guiding ideal therapeutic interventions.
